Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Magnetic Marker Monitoring (MMM) Study With Gel Matrix Tablets Under Fasting and Fed Conditions

Phase 1

Completed

Conditions: Time for Colon Arrival
Gastrointestinal-transport
Small Intestinal Transit Time
Food Effect
Magnetic Marker Monitoring
Gastric Emptying Time

Interventions: Drug: D1000085
Drug: D1000082
Drug: D1000083
Drug: D1000078

First Posted Date: 2010-10-20

Last Posted Date: 2010-11-04

Lead Sponsor: AstraZeneca

Target Recruit Count: 5

Registration Number: NCT01224587

Locations: 🇩🇪
Research Site, Berlin, Germany

Safety and Efficacy Study of ONGLYZA (Saxagliptin) Under Conditions of Actual Use

Terminated

Conditions: Type 2 Diabetes Mellitus

First Posted Date: 2010-10-19

Last Posted Date: 2013-10-08

Lead Sponsor: AstraZeneca

Target Recruit Count: 542

Registration Number: NCT01223456

Locations: 🇵🇭
Research Site, Manila, Philippines

A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function

Phase 1

Completed

Conditions: Hepatic Impairment
Healthy Volunteers
Pharmacokinetics
Amount of R406 in Blood

Interventions: Drug: Fostamatinib

First Posted Date: 2010-10-18

Last Posted Date: 2011-07-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 32

Registration Number: NCT01222455

Locations: 🇺🇸
Research Site, Orlando, Florida, United States

To Evaluate the Effect of AZD3199 on the Electrical Activity in the Heart

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease
Lung Disease

Interventions: Drug: AZD3199
Drug: Moxifloxacin
Other: Placebo comparator

First Posted Date: 2010-10-18

Last Posted Date: 2011-02-16

Lead Sponsor: AstraZeneca

Target Recruit Count: 40

Registration Number: NCT01222442

Locations: 🇬🇧
Research Site, London, UK, United Kingdom

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] AZD2423 in Volunteers

Completed

Conditions: Neuroscience

Interventions: Drug: AZD2423

First Posted Date: 2010-10-18

Last Posted Date: 2011-02-08

Lead Sponsor: AstraZeneca

Target Recruit Count: 6

Registration Number: NCT01223014

Locations: 🇬🇧
Research Site, London, United Kingdom

A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus
High Blood Sugar

Interventions: Drug: AZD1656

First Posted Date: 2010-10-15

Last Posted Date: 2012-01-19

Lead Sponsor: AstraZeneca

Target Recruit Count: 20

Registration Number: NCT01221519

Locations: 🇺🇸
Research Site, St. Paul, Minnesota, United States

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics After High Single Ascending Oral Doses of AZD1656 in T2DM Patients

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: AZD1656
Drug: Placebo

First Posted Date: 2010-10-15

Last Posted Date: 2011-02-17

Lead Sponsor: AstraZeneca

Target Recruit Count: 24

Registration Number: NCT01221545

Locations: 🇺🇸
Research Site, Chula Vista, California, United States

Centralized Pan-Russian Survey on the Undertreatment of Hypercholesterolemia

Completed

Conditions: Dyslipidaemia

First Posted Date: 2010-10-15

Last Posted Date: 2012-03-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 1000

Registration Number: NCT01221584

Locations: 🇷🇺
Research Site, Yaroslavl, Russian Federation

Safety and Efficacy Study of CUBICIN (Daptomycin) Under Conditions of Actual Use

Withdrawn

Conditions: Complicated Skin and Skin Structure Infections and Bacteremia Including Right-sided Endocarditis

First Posted Date: 2010-10-13

Last Posted Date: 2011-09-28

Lead Sponsor: AstraZeneca

Target Recruit Count: 200

Registration Number: NCT01219114

Locations: 🇵🇭
Research Site, Quezon City, Metro Manila, Philippines

A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.

Phase 1

Terminated

Conditions: Solid Tumour
Advanced Solid Malignancies
Child-Pugh A to B7 Advanced Hepatocellular Carcinoma
EGFR and/or ROS Mutant NSCLC
Lung Metastasis Carcinoma
Gastric Cancer

Interventions: Drug: AZD1480 Daily
Drug: AZD1480 BID

First Posted Date: 2010-10-13

Last Posted Date: 2013-01-08

Lead Sponsor: AstraZeneca

Target Recruit Count: 47

Registration Number: NCT01219543

Locations: 🇰🇷
Research Site, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy